|
Identifying molecular drivers of tumor heterogeneity in pancreatic cancer
|
1F31CA224792-01A1
|
$36,672
|
|
ADAMS, CHRISTINA
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-05S1
|
$2,256,906
|
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Image-guided irreversible electroporation directed CAR T-cell delivery to solid tumors
|
1R01CA236615-01
|
$392,764
|
|
ADUSUMILLI, PRASAD
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Molecular mechanism of bitter melon juice efficacy against pancreatic cancer.
|
3R01CA195708-05S1
|
$94,087
|
|
AGARWAL, RAJESH
|
UNIVERSITY OF COLORADO DENVER
|
|
Policy- and Provider-Level Determinants of Human Papillomavirus Vaccination Disparities Among Young U.S. Women
|
1K01CA234226-01
|
$158,403
|
|
AGENOR, MADINA
|
TUFTS UNIVERSITY MEDFORD
|
|
Network Lead Academic Participating Site: Memorial Sloan-Kettering Cancer Center
|
3U10CA180791-04S1
|
$145,357
|
|
AGHAJANIAN, CAROL
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Targeting galectin-3 to overcome drug resistance in metastatic prostate cancer therapy
|
1R43CA228813-01A1
|
$300,000
|
|
AHMED, HAFIZ
|
GLYCOMANTRA, INC.
|
|
Chemically produced neural progenitors loaded with ferumoxide-protamine sulfate complex for visualization of gliomas
|
1R43CA228726-01A1
|
$300,000
|
|
ALEXANIAN, ARSHAK
|
CELL REPROGRAMMING AND THERAPEUTICS, LLC
|
|
Commercialization of a proprietary Ga-68 PSMA-targeted drug for PET imaging in recurrent prostate cancer
|
1R44CA233140-01
|
$299,412
|
|
ALEXOFF, DAVID
|
FIVE ELEVEN PHARMA, INC.
|
|
Novel Strategies for Precision T-cell Therapies
|
3R01CA198095-03S1
|
$107,431
|
|
ALMO, STEVEN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Immunophenotyping by CyTOF and machine learning
|
ZIA BC 011807
|
$198,401
|
$39,680
|
Altan-Bonnet, Gregoire
|
CCR (NCI)
|
|
Consolidated Basic Cancer Research Program
|
3P30CA010815-49S1
|
$142,498
|
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Developing Human Induced Pluripotent Stem Cell Precision Oncology Models
|
1R50CA233164-01
|
$155,981
|
|
ANASTASAKI, CORINA
|
WASHINGTON UNIVERSITY
|
|
Resource stratified phased implementation frameworks to improve breast healthcare
|
1R13CA224776-01A1
|
$50,000
|
|
ANDERSON, BENJAMIN
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Eco-Evolutionary dynamics of NSCLC to immunotherapy: Response and Resistance
|
1U01CA232382-01
|
$688,043
|
|
ANDERSON, ALEXANDER
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
Defining the Transcriptional Regulation and Genomic Organization of FAIM3 and PIGR, Human Ig Receptors Involved in Immunity, Auto-Immune Disease, and Lymphoma
|
5F31CA221012-02
|
$30,434
|
$15,217
|
ANDREWS, JARED
|
WASHINGTON UNIVERSITY
|
|
Targeting the adenosine A2A receptor immune checkpoint in lung cancer patients
|
3R01CA201124-03S1
|
$189,200
|
|
ANTONIA, SCOTT
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
Multiscale proteomics studies of DNA repair and genomic stability
|
1R50CA233182-01
|
$162,365
|
|
APARICIO CASADO, TOMAS
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Development of an MRI-compatible, High-Frequency Irreversible Electroporation (H-FIRE) System for Non-thermal Ablation of Inoperable Brain Tumors
|
1R43CA233158-01
|
$244,498
|
|
ARENA, CHRISTOPHER
|
VOLTMED, INC.
|
|
Cancer Genetics of Short Telomere Syndromes
|
1R01CA225027-01A1
|
$530,521
|
|
ARMANIOS, MARY
|
JOHNS HOPKINS UNIVERSITY
|
|
Predicting the Presence of Clinically Significant Prostate Cancer using Multiparametric MRI and MR-US Fusion Biopsy
|
1R21CA220352-01A1
|
$195,568
|
|
ARNOLD, COREY
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
Role of HER2 mutations in breast cancer progression and response to targeted therapies
|
1R01CA224899-01A1
|
$382,641
|
|
ARTEAGA, CARLOS
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
T Cell Alternative p38 Activation Pathway
|
ZIA BC 010774
|
$298,466
|
$298,465
|
Ashwell, Jonathan
|
CCR (NCI)
|
|
Glucocorticoids and T cell development and function
|
ZIA BC 011264
|
$298,466
|
$298,465
|
Ashwell, Jonathan
|
CCR (NCI)
|
|
T cell receptor proximal signaling
|
ZIA BC 011715
|
$596,931
|
$298,465
|
Ashwell, Jonathan
|
CCR (NCI)
|
|
Cancer Center Support Grant
|
2P30CA082103-19
|
$7,954,381
|
$79,544
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA082103-19S1
|
$84,000
|
$840
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA082103-19S2
|
$206,488
|
$2,065
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA082103-19S3
|
$257,838
|
$2,578
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Ultrasound-based diagnostic and monitoring of bladder cancer treatment with drug released from nanoparticles
|
1R43CA232778-01
|
$295,240
|
|
ASSOULINE, JOE
|
NANOMEDTRIX, LLC
|
|
Cone Beam Tomosynthesis Fluoroscopy for Image Guided Interventions
|
3R43CA228158-01A1S1
|
$50,000
|
|
ATRIA, CRISTIAN
|
NVIEW MEDICAL, INC.
|
|
Obesity and Pancreatic Cancer Progression and Survival
|
1K07CA222159-01A1
|
$149,125
|
|
BABIC, ANA
|
DANA-FARBER CANCER INST
|
|
Targeting macrophages to reduce colorectal cancer: Impact of metabolic reprogramming
|
1F99CA234920-01
|
$35,718
|
|
BADER, JACKIE
|
UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA
|
|
Obesity, related comorbidities, and breast cancer outcomes in African Americans
|
3R01CA185623-05S1
|
$68,187
|
|
BANDERA, ELISA
|
RBHS -CANCER INSTITUTE OF NEW JERSEY
|
|
Characterizing the resistance mechanisms to BET-bromodomain inhibition in MYC-amplified medulloblastoma
|
4R00CA201592-03
|
$249,000
|
|
BANDOPADHAYAY, PRATITI
|
DANA-FARBER CANCER INST
|
|
Bayesian learning algorithms for identifying and classifying heterogeneity of cell types in variety of solid tumors
|
1R21CA231892-01
|
$167,475
|
|
BANERJEE, ANJISHNU
|
MEDICAL COLLEGE OF WISCONSIN
|
|
Dual View Endoscopy for Colonoscopy
|
2R42CA203212-02
|
$872,389
|
|
BANERJEE, BHASKAR
|
OMNISCIENT, LLC
|
|
Contribution of development and age to breast cancer etiology
|
3R01CA190980-04S1
|
$58,563
|
|
BARCELLOS-HOFF, MARY
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Targeting the Major Histocompatibility Class I-LILRB1 signaling axis for cancer immunotherapy by macrophages
|
1F30CA232472-01
|
$43,039
|
|
BARKAL, AMIRA
|
STANFORD UNIVERSITY
|
|
Anatomic Pathology Residency Program
|
ZIE BC 011384
|
$1,537,925
|
$61,517
|
Barr, Frederic
|
CCR (NCI)
|
|
Memory potential, molecular characterization, and translational applications of the novel ThEO/TcEO T cell phenotype
|
4K00CA212447-03
|
$71,280
|
|
BARTKOWIAK, TODD
|
VANDERBILT UNIVERSITY
|
|
Gaining Metabolic Insight in Older Men undergoing Androgen Deprivation Therapy for Prostate Cancer
|
1R01CA226211-01A1
|
$485,064
|
|
BASARIA, SHEHZAD
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Analyzing and Interpreting PRO-CTCAE with CTCAE and Other Clinical Data to Characterize Drug Tolerability
|
1U01CA233046-01
|
$595,910
|
|
BASCH, ETHAN
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
Cancer Center Support Grant
|
3P30CA042014-29S1
|
$125,000
|
|
BECKERLE, MARY
|
UNIVERSITY OF UTAH
|
|
Cancer Center Support Grant
|
3P30CA042014-29S2
|
$250,000
|
|
BECKERLE, MARY
|
UNIVERSITY OF UTAH
|
|
Cancer Center Support Grant
|
3P30CA042014-29S3
|
$248,625
|
|
BECKERLE, MARY
|
UNIVERSITY OF UTAH
|
|
Cancer Center Support Grant
|
3P30CA042014-29S4
|
$114,251
|
|
BECKERLE, MARY
|
UNIVERSITY OF UTAH
|
|
The role of AXL-ABL axis in Barretts carcinogenesis
|
3R01CA193219-04S1
|
$58,182
|
|
BELKHIRI, ABBES
|
VANDERBILT UNIVERSITY MEDICAL CENTER
|
|
Sialylation-dependent mechanisms driving pancreatic cancer progression
|
1U01CA233581-01
|
$564,739
|
|
BELLIS, SUSAN
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
Cancer Center Support Grant
|
3P30CA022453-36S1
|
$131,250
|
|
BEPLER, GEROLD
|
WAYNE STATE UNIVERSITY
|
Total relevant funding to Autoimmune Diseases for this search: $11,092,520
|